Eisai has made an £11.5 million ($15.2 million) investment to fund two new packaging lines and create new jobs at its Hatfield production plant in Hertfordshire.   Following a succession of approvals and reimbursements across the world for its cancer therapy, Lenvima (lenvatinib), Eisai is now expanding its facilities to triple product output within the next three years and is targeting a four-fold increase by 2025 to meet global demand.   Transforming Manufacturing Operations   The expansion co...